An Israeli study found that the fourth dose of the Covid-19 vaccine was able to raise antibodies to higher levels than the third dose, but the researchers found that was still not enough to prevent Omicron variant infection, researchers at Israel’s Sheba Medical Center said on Monday.
The Israeli hospital said it was the world’s first trial to look at the fourth combined vaccination, adding that the findings were preliminary and had not yet been published.
About 150 participants in the study received a fourth dose of the BioNTech-Pfizer vaccine, while another 120 participants received Moderna’s fourth dose. All received a third BioNTech-Pfizer booster. They were then compared to a control group that did not receive the fourth injection.
“The rise in antibody levels that we saw at Moderna and Pfizer was slightly higher than what we saw after the third booster vaccine,” said Gili Regev-Yochay, principal investigator and director of the infectious disease division.
Complete News Source : Hindustan Times
